Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) Invested Capital (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Invested Capital for 4 consecutive years, with $5.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 21.9% to $5.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.1 million, a 21.9% decrease, with the full-year FY2024 number at $4.7 million, down 34.18% from a year prior.
  • Invested Capital was $5.1 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from $3.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $8.7 million in Q3 2023 to a low of -$23.3 million in Q4 2022.
  • A 4-year average of -$4.3 million and a median of $4.1 million in 2024 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: skyrocketed 138.63% in 2023, then tumbled 39.35% in 2025.
  • 60 Degrees Pharmaceuticals' Invested Capital stood at -$23.3 million in 2022, then skyrocketed by 130.47% to $7.1 million in 2023, then plummeted by 34.18% to $4.7 million in 2024, then grew by 10.0% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Invested Capital are $5.1 million (Q3 2025), $3.1 million (Q2 2025), and $4.7 million (Q1 2025).